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Abstract 
Background: Immunomodulatory interventions play a key role in the treatment of infections and 
cancer as well as allergic diseases. Adjuvants such as micro- and nanoparticles are often added to 
immunomodulatory therapies to enhance the triggered immune response. Here, we report the 
immunological assessment of novel and economically manufactured microparticle adjuvants, namely 
strontium-doped hydroxyapatite porous spheres (SHAS), which we suggest for the use as adjuvant 
and carrier in allergen-specific immunotherapy (ASIT).  
Methods and Results: Scanning electron microscopy revealed that the synthesis procedure 
developed for the production of SHAS results in a highly homogeneous population of spheres. SHAS 
bound and released proteins such as ovalbumin (OVA) or the major cat allergen Fel d 1. SHAS-OVA 
were taken up by human monocyte-derived dendritic cells (mdDCs) and murine DCs and did not 
have any necrotic or apoptotic effects even at high densities. In a murine model of ASIT for allergic 
asthmatic inflammation we found that OVA released from subcutaneously injected SHAS-OVA led to 
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a sustained stimulation of both CD4+ and CD8+ T-cells. ASIT with SHAS-OVA as compared to soluble 
OVA resulted in similar humoral responses but in a higher efficacy as assessed by symptom scoring.  
Conclusion: We conclude that SHAS may constitute a suitable carrier and adjuvant for ASIT with 
great potential due to its unique protein-binding properties. 
 
Keywords: allergy model, dendritic cells, immunotherapy, microparticles 
 
Introduction 
The mechanisms by which micro- and nanoparticles enhance immune responses to antigens are 
diverse and include the delivery of antigens and the direct stimulation of the immune cells, as 
recently reviewed (1). The administration of an antigen in a particulate form has been postulated to 
enhance its stability and integrity and to create a so-called depot effect, where the antigen is 
gradually released, thus prolonging the challenge of the immune system (2).  
Allergen-specific immunotherapy (ASIT) is used as a desensitizing therapy for allergic diseases and is 
a specific and potentially curative treatment. The mechanisms of action of ASIT include the 
modulation of T- and B-cell responses and related antibody isotypes, as well as the regulation of 
eosinophils, basophils and mast cells in terms of migration to the tissues and release of mediators 
(3). Dendritic cells (DCs) as primer of the adaptive immune response are key cells for a successful 
ASIT. Recent research identified several subsets of DCs equipped with different functional 
properties, ranging from tolerance-induction to the promotion of specific immune responses (4). 
Subcutaneous immunotherapy protocols generally involve daily to weekly injections during a build-
up phase, followed by monthly maintenance injections for a period of 3–5 years (5). A prolonged 
presence of the antigen is needed for the induction of tolerance. Current ASIT protocols are time-
consuming which leads to a low compliance of patients. Better therapeutic options are needed to 
meet this medical need.  
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The strontium-doped hydroxyapatite porous spheres (SHAS) used in this study are the result of an 
optimized synthesis procedure that allows for controlling their size, porosity and morphology (6). 
Similar spheres, hollow calcium phosphate spheres, have been shown to bind consistent amounts 
(~0.37 mg/mg) of the antibiotics vancomycin and cephalothin, which are then slowly released over 
many hours in vitro (7). In this study, we evaluated the potential of SHAS as a matrix for a prolonged 
local delivery of protein antigen, and we assessed their potential as a tolerance-inducing adjuvant 
for immunotherapeutic interventions, specifically ASIT. 
 
 
Material and Methods 
Preparation and characterization of SHAS, strontium-doped hydroxyapatite porous spheres  
NaCl, KCl, Na2HPO4, and KH2PO4 were dissolved in sterile water at a molar ratio of 137.0 : 2.7 : 8.1 : 
1.5 : 0.5. After addition of calcium chloride (1 mM), magnesium chloride (0.05 mM) and strontium 
nitrate (0.6 mM), the mixture was heated at 100°C. After 6 hours, the precipitation was filtered and 
washed twice with room-temperature ethanol. All chemicals were purchased from Sigma-Aldrich 
(Steinheim, Germany) at the highest purity grade available. The morphology of the spheres before 
and after OVA adsorption was analyzed by Field Emission Scanning Electron Microscopy (FE-SEM, 
LEO 1550, Zeiss, Germany). Powder X-ray diffraction (XRD, Siemens Diffractometer D5000, Siemens, 
Munich, Germany) using Cu Kα radiation (λ = 1.5418 Å) operated at 40 kV and 40 mA at a 2θ range of 
5° - 60°C was used to analyze the crystallinity of SHAS. Surface area and porosity were estimated 
from the N2 sorption isotherm, which was performed by Accelerated Surface Area and Porosimetry 
(ASAP 2020, Micromeritics, Norcross, GA, United States) in accordance with the Brunauer-Emmet-
Teller principle. The ion composition was analyzed using inductive coupled plasma optical emission 
spectroscopy (ICP-OES, Optima 5300DV; Perkin-Elmer, Waltham, MA, United States). The zeta-
potential of the particles was measured in PBS at 25°C and 37°C by laser Doppler velocimetry on a 
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ZetaSizer Nano instrument (Malvern Instruments, UK). The refraction indexes used were of 1.63 for 
the particles. LPS  contamination was ruled out indirectly measuring NF-B activation in human 
mdDCs (data not shown).  
 
Ovalbumin labeling  
Grade VI OVA (Sigma-Aldrich) and Dylight 488 Amine-Reactive Dye (Thermo Scientific, Rockford, IL, 
United States) were used to produce labeled OVA488. To this end, OVA was suspended in phosphate 
buffered saline (PBS) at a concentration of 2 mg/ml, sterilized by filtration and added to the vial 
containing the dye. After 3 h incubation at room temperature and 12 h at 4°C, the unreacted dye 
was removed by dialysis against PBS with a SpectraPor Membrane with a molecular weight cut-off of 
6-8 kDa (Spectrum Labs, Roncho Domingues, CA, United States) and 4 buffer exchanges over 36 h.  
 
Protein loading of SHAS  
SHAS (1-5 mg) were suspended in 500 l PBS and put in a sonication bath five times for 10 s in order 
to obtain a homogeneous solution. Between each sonication burst the tubes were shaken by hand. 
The SHAS were allowed to stand for 5 min, centrifuged (2000 x g, 2 min), and washed once with 500 
l PBS. Afterwards they were suspended in 300 l of 1 mg/ml protein solution per mg of particles 
and left overnight under constant shaking. Thereafter, the beads were collected by centrifugation 
(2000 x g, 2 min) and the protein concentration in the supernatant was determined by Bradford 
(Biorad, Hercules, CA, United States) to calculate the amount of protein loaded. The major cat 
allergen Fel d 1, used as a protein loading control for SHAS, was produced in E. coli and purified as 
described (8). LPS decontamination was ruled out indirectly measuring NF-B activation in human 
mdDCs (data not shown).  
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In vitro release 
Two mg of OVA488-loaded SHAS were suspended in 200 l PBS or PBS-Tween20 (0.05%) and kept in 
suspension by rolling at room temperature. Spontaneous release was monitored by measuring the 
protein concentration in the supernatant after 20 h. The quality of the protein released was 
visualized by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). Residual 
protein bound to the SHAS was released by incubation for 5 min at 90°C in SDS-PAGE loading buffer 
(50 mM Trizma-HCl pH8, 5% glycerol, 2.5% β-mercaptoethanol, 50 g/ml bromophenol blue, 10% 
dithiothreitol, all from Sigma-Aldrich). 
 
Preparation of monocyte-derived dendritic cells (mdDCs) 
Human mdDCs were prepared from peripheral blood mononuclear cells from healthy donors with 
written informed consent. The CD14+ population was isolated by AutoMACS using CD14 microbeads 
(Miltenyi Biotec, Bergisch Gladbach, Germany) and cultured at 106/ml in 6-well plates in cRPMI 
(RPMI 1640, 10% heat-inactivated FCS, 2 mM L-glutamine, 1 mM sodium pyruvate, 1x MEM 
vitamins, 1x MEM non-essential amino acids, 100 U/ml penicillin, 100 µg/ml streptomycin, 100 
µg/ml kanamycin, all from Sigma-Aldrich) in the presence of 1000 U/ml GM-CSF (PeproTech, 
Hamburg, Germany) and 1000 U/ml IL-4 (Novartis, Basel, Switzerland) for 5 days. The successful 
differentiation to human mdDCs was confirmed by flow cytometric CD11c staining (clone 3.9, 
Biolegend, Biolegend, San Diego, USA) together with the viability staining agent eFluor 780 
(eBioscience, Vienna, Austria, data not shown). Cells were stained and analyzed using a FACS LSRII or 
a Canto system with DIVA software (BD Biosciences). 
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In vitro toxicity, apoptosis detection assays 
100, 10, or 1 g of SHAS were added to 2 x 105 human mdDCs in 200 l cRPMI in a 96-well plate. 
After 24 h incubation, the cells were stained for Annexin and 7AAD with the PE Annexin V Apoptosis 
Detection Kit I (BD Biosciences, Erembodegen-Aalst, Belgium) and analyzed by flow cytometry. 
 
Mice  
 7-10 weeks old female B6 wild type, C57BL/6 or BALB/c mice were housed under specific pathogen 
free (SPF) conditions and handled in accordance with French and European directives with ethical 
approval from the Centre d’Immunologie de Marseille-Luminy. OT-I and OT-II mice have been 
previously described (9, 10).  
 
Sensitization and immunotherapy models  
The models are described in Fig. S1. 
Preparation and adoptive transfer of labeled OT-I and OT-II cells 
OVA-specific CD8+ (OT-I) and OVA-specific CD4+ (OT-II) T-cells were isolated as previously described 
(11), labeled with CellTrace Violet (CTV, Invitrogen), adoptively transferred and after 3 days isolated 
from the spleen and analyzed by flow cytometry (see Fig. S1A).  
Flow cytometry of mouse cells  
Single cell suspension of lymph nodes were produced as previously described (11). Cells were 
stained and analyzed using a FACS LSRII or a Canto system with DIVA software (BD Biosciences). Cell 
viability was evaluated using Sytox (Invitrogen Detection Technologies, Eugene, USA).  
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Anti-CD3 (17A2) was from Biolegend (San Diego, USA), TCR V2 (6D6.6) from Abcam, anti-CD45.1 
(A20) from eBioscience, anti-CD4 (RM4-5), and anti-CD8 (53-6.7) were from BD Pharmingen (San 
Diego, USA).   
For the analysis of the nodal DCs the following antibodies were additionally used: anti-NK1.1 
(PK136), anti-CD19 (6D5), anti–Ly-6G (1A8) and anti-CD64 (X54-5/7.1) from BioLegend; anti-CD11b 
(M1/70), anti-CD11c (N418),  anti–MHC class II (MHC II; I-A/I-E) (M5/114.15.2) and anti-CD24 
(M1/69) from eBioscience.  
Analyses were performed on living CD45+ cells. Prior to analyzing DCs, we systematically gated out B 
cells, T cells, NK cells, macrophages and neutrophils using a dump channel corresponding to cells 
positive for CD19, CD3, NK1.1, CD64 or Ly-6G cells. The migratory DCs were characterized as MHC-
IIhigh and CD11clow-high. We further discriminated migratory DCs into CD11b+CD24- and CD24+ cells.  
Analysis was performed using FlowJo software (Tree Star, Inc., Ashland, OR, USA). 
 
Microscopy 
Fluorescent OVA (OVA488) labeled SHAS (prepared as described above) were added to 300’000 
mdDCs at a concentration of 25 g/ml in cRPMI. After 12 h the cells were washed once with PBS and 
resuspended in 200 l PBS at 37°C. CellMask Orange Plasma membrane Stain (Thermo Scientific) 
was diluted 1:5000 in PBS, vortexed for 30 s and sonicated for 1 min. After warming at 37°C for 3 
min in a water bath 100 l of this solution was added to the mdDCs and incubated by rolling for 10 
min at room temperature. Stained cells were washed twice with PBS and brought onto a microscope 
slide by cytospin (500 rpm, 2 min), fixed with 4% paraformaldehyde (Sigma-Aldrich), covered with 
Prolong Gold Antifade Reagent with DAPI (Life Technologies) and visualized by a Leica TCS SPE 
confocal microscope (Leica Microsystems, Heerbrugg, Switzerland). 
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Immunoglobulin ELISA 
Nunc-Immuno Clear Flat-Bottom Maxisorp 96-well plates (Thermo Scientific) were coated by 
overnight incubation at 4°C with 100 l of 10 g/ml OVA in PBS. Unspecific bindings were avoided by 
1 h incubation in 150 l blocking buffer (1% BSA and 5% sucrose in PBS, all from Sigma-Aldrich). 
After washing, 100 l diluted sera (1:10 for IgE, 1:100 for IgG2a, 1:100’000 for IgG1) were added and 
incubated for 3 h. OVA-specific antibodies were detected with 100 l of the corresponding 
biotinylated anti-isotype at 0.5 g/ml and incubated for 2 h. After 45 min incubation with 
Streptavidin-HRP diluted 1:200 (R&D Systems, Minneapolis, MN, United States), bound antibodies 
were detected with OptiEIA TMB Substrate Reagent (BD Biosciences). Antibodies, sera and enzymes 
were diluted in PBS containing 1% BSA. Between each step, plates were washed 3 times with PBS-
Tween (0.05%). The following anti-isotype antibodies were used: biotin anti-mouse IgE (RME-1), 
biotin anti-mouse IgG1 (RMG1-1), and biotin anti-mouse IgG2a (RMG2a-62; all from Biolegend). 
Serum concentrations were calculated by 4-parametric curve regression using the following 
antibodies as standards (50-0.4 ng/ml): mouse anti-OVA IgE (2C6; AbD Serotec, Raleigh, NC, USA), 
mouse anti-denatured OVA IgG1 and mouse anti-denatured OVA IgG2a (6C8, 6G2; Thermo Scientific). 
 
Bronchoalveolar lavage 
Mice were sacrificed by intraperitoneally injection of pentobarbital (150 mg/kg, Streuli Pharma AG, 
Uznach, Switzerland). Broncho alveolar lavage (BAL) was performed by sealing the upper part of the 
trachea with medical tweezers and injecting 1 ml PBS containing the cOmplete proteinase inhibitor 
cocktail (Roche, Mannhein, Germany), using a 1 ml syringe with a bent 26G needle. Determination of 
cell type and content in BAL was determined by Romanowski stain (Diff-Quick, Medion Diagnostics, 
Düdingen, Switzerland) for cell subsets. 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Behavioral assessments 
To assess pain or discomfort, mice were observed in an open-field test. After immunotherapeutic 
injections every mouse was allowed to rest for 45 min in the home cage. Afterwards it was 
transferred to a 30x50 cm cage divided into 10x10 cm squares and observed for 3 min. The following 
parameters were recorded and scored as follows: fur (1 point if crumpled, 2 points if very sweaty), 
posture (1 point if the mouse was crooked, 2 points for no locomotion), movement (full body access 
to the 10 cm sectors, 1 point for only entering 4-10 sectors, 2 points for only entering 1-3 sectors), 
rearing behavior (1 point if absent), urination and defecation (1 point if absent). The cage was 
cleaned first with a humid cloth and then with a dry one before starting the experiment with 
another animal (adapted from (12, 13). 
 
Statistical analysis 
The Wilcoxon-Mann-Whitney-Test was used to assess statistical significance. Probability values are 
expressed as the following: ***, p<0.001; **, p<0.01; *, p<0.05; NS, non significant. 
 
Results  
 
Physical characterization of SHAS 
The synthesis procedure developed for the production of SHAS resulted in a homogeneous 
population of spheres as assessed by scanning electron microscopy (Fig. 1A). The molar ratio of their 
composition was 1.00 (Magnesium) : 2.15 (Strontium) : 3.85 (Calcium) : 5.42 (Phosphate). SHAS 
mainly consisted of hydroxyapatite as shown by X-ray diffraction analysis, where peaks were 
coherent with the joint committee on powder diffraction standards (JCPDS) data (JCPDS-09-
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0432/1996, Fig. 1B). The zeta-potential of SHAS in PBS resulted in a negative value of -10.5 ± 1.3 mv 
(mean ±SEM, n>3) at 25° C and of -12.1 ± 4.0 mv at 37° C.  
The spheres exhibited a spherical and porous shape. Scanning electron microscopy showed an 
average diameter of 1.8 m, with a range of 1.3 – 2.5 m. The pore size of 33.1 nm in spheres was 
obtained from BET analysis (Fig. 1C). One mg of SHAS bound approximately 90 g of both the model 
antigen OVA and the control protein Fel d 1, the major cat allergen (Fig. 1D). OVA binding did not 
influence the morphology of SHAS as demonstrated by electron microscopy (Fig. 1C), and the 
particle-bound OVA did not appear degraded or modified after spontaneous or Tween20-induced 
release (Fig. 1E).  
 
OVA-loaded SHAS is taken up by human mdDCs without toxic and apoptosis inducing side effects in 
vitro 
In order to test the compatibility and properties of SHAS on human antigen-presenting cells we 
added the particles to mdDCs. DyLight488 labelled OVA (OVA488), previously loaded on SHAS (SHAS- 
OVA488), was taken up and internalized by human mdDCs after 1 h incubation (Fig. 2A). No difference 
in toxicity or apoptosis induction compared to untreated human mdDCs was seen when different 
concentrations of soluble OVA488, SHAS- OVA488 or SHAS alone were added to the cells (Fig. 2B).  
 
Uptake of antigens by DCs in vivo 
To quantify the uptake of antigens in vivo, we injected either soluble OVA labeled with DyLight488 
(OVA488), OVA488 bound to microparticles (SHAS-OVA488), or PBS subcutaneously into the lumbar area 
of B6-WT mice which were sacrificed 1, 4 or 7 day(s) after injection. Then we analyzed the migrated 
DCs in the draining inguinal lymph nodes for their uptake of OVA488 by flow cytometry.  
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DyLight488
+ cells were detectable among migratory DCs 1 day after injection of both OVA488 and of 
SHAS-OVA488 (Fig. 2C). We further discriminated DCs cells into CD11b
+CD24- and CD24+ cells and 
among the CD11b+CD24+ DCs we see a small but consistent uptake of OVA488 bound to SHAS, which 
persisted for the total period of investigation of 7 days (Fig. 2D).  
 
SHAS-OVA induces a stronger OVA-specific CD4+ and CD8+ T- cell proliferation compared to OVA 
To test whether targeting DCs with antigen-loaded SHAS can induce the activation of antigen-specific 
T cells in vivo, we injected SHAS-OVA or soluble OVA subcutaneously in mice. After 3, 6 or 8 days, 
mice were adoptively transferred with CTV labeled OT-I CD8+ T cells and OT-II CD4+ T cells. They 
express a TCR specific for an OVA-derived peptide presented by H-2Kb and for an OVA-derived 
peptide presented by H2-Ab, respectively (9, 10). Three days after adoptive transfer, the extent of 
OT-I and OT-II cell proliferation was determined by CTV dilution (Fig. S1A). SHAS-OVA triggered a 
significantly higher proliferation of OT-I and OT-II cells than soluble OVA (Fig. 3A, B). Furthermore, 
SHAS-OVA, but not soluble OVA, resulted in sustained T cell proliferation for up to 6 and 8 days in 
CD4+ and CD8+ T cells, respectively.  
 
OVA-specific IgE and IgG responses to SHAS-bound OVA are comparable to those obtained with 
soluble OVA  
Next, we wanted to investigate the induction of antigen specific IgE and IgG production in response 
to SHAS-OVA compared to soluble OVA. To do so, we used a standard protocol for sensitization to 
allergens consisting of a sensitization period with three weekly injections of SHAS-OVA or the 
adequate amount of OVA as well as injections with Alum-OVA, PBS and SHAS alone as controls. 
Following the sensitization period, the challenge consisted of three injections of OVA at days 26, 27 
and 28 (Fig. S1B).  
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Humoral responses, in particular serum levels of antigen-specific IgE, IgG1 and IgG2a, were 
comparable in mice immunized with SHAS-OVA and soluble OVA. (Fig. 4A-C). Moreover, following 
aerosol allergen challenge, the amount of eosinophils in the BAL fluid was comparable for 
sensitization with OVA, SHAS-OVA and Alum-OVA, indicating analogous levels of allergic sensitization 
(Fig. 4D). 
 
SHAS immunotherapy has increased efficacy 
 
To assess the potential of SHAS as an antigen-carrier for immunotherapeutic interventions for 
allergic diseases, we used a rush immunotherapy protocol consisting of a sensitization period 
followed by treatment with OVA, SHAS-OVA or protein-free SHAS. As control, we also added a group 
of mice (OVA-ctrl) treated more frequently and with a higher dose of OVA (14). After the treatment, 
mice were challenged with OVA (Fig. S1C). Behavioral assessments evaluated pain and discomfort 
using a symptom score as described in the material and methods section. Immunotherapy using 
SHAS-OVA showed a stronger reduction of the symptoms assessed following both the first and the 
last immunotherapeutic injection than did soluble OVA or SHAS alone (Fig. 5A, B). Regarding the 
other parameters assessed, such as eosinophils in BAL and antigen specific IgG1, no difference was 
seen between the groups treated with SHAS-OVA, soluble OVA or SHAS alone (Fig. 5C, D).  
Discussion 
ASIT is a safe and effective treatment for type I respiratory allergies in humans. Better adjuvants 
could further improve ASIT, allowing to decrease the allergen dose and to simplify immunization 
schemes. The present study showed that the use of SHAS, strontium-doped hydroxyapatite spheres, 
in ASIT can help to target the allergen to DCs and thereby enhance ASIT efficacy. Specifically, SHAS 
can bind allergens, facilitate allergen-specific immune response and improve the clinical outcome of 
ASIT.   
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The loading of SHAS with the model allergen OVA enhances OVA stability and integrity, 
creates sustained release and depot effects, and results in sustained immune responses after 
application in vivo.  One single subcutaneous injection of the antigen-loaded particles was sufficient 
to induce antigen-specific CD8+ and CD4+ effector T cells over at least 6 days. Allergens loaded on 
SHAS are taken up by dendritic cells and the microparticles do not have toxic or apoptosis-inducing 
effects. Importantly, in a mouse model of ASIT, SHAS-OVA led to a better symptom reduction 
compared to OVA alone. OVA488 released from SHAS-OVA488 was mostly taken up by CD11b
+ DCs. 
This DC subset constitutively produces retinoic acid and induces Foxp3+ regulatory T cells (15). 
Targeting of this tolerogenic CD11b+ DC subset could thus be one possible explanation for the 
successful ASIT using SHAS-bound proteins.   
A main advantage of the use of allergen-delivery systems in immunotherapy is that the 
antigen release is continuous, which could make single shot treatments as effective as the currently 
employed and less convenient multiple dosage protocols (16, 17). Biodegradable nanoparticles such 
as SHAS encapsulate allergens so that they are delivered in vivo in a delayed-continuous or pulsatile 
manner to modulate the resultant immune response and decrease the potential for adverse events 
(18). Our study supports this hypothesis as the injection with the slowly and continuously released 
OVA bound to SHAS resulted in a better response compared to the injection of the soluble, directly 
available OVA.  
We have previously shown that the production of SHAS is straightforward, relatively 
inexpensive and robust (6). SHAS have been hitherto used as biomaterial for bone reconstruction, 
and now for the first time they are used in the field of immunology (19, 20). Here, we show that ASIT 
with SHAS-bound allergen is more effective than immunotherapy with soluble allergen.  Taken 
together, these findings recommend further development of SHAS for the use in allergen-specific 
immunotherapy.  
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Figure Legends 
 
Fig. 1 Characterization of SHAS and their protein binding properties  
 
A) The population of beads as result of the synthesis procedure developed for the creation of SHAS. 
B) X-Ray diffraction pattern of SHAS and hydroxyapatite. C) Representative SEM images of SHAS 
before (left) and after OVA binding (right). D) Binding of OVA and the major cat allergen Fel d 1 to 
SHAS, determined by subtracting the amount of unbound protein in the supernatant after the 
adsorption process from the initial amount. Results are expressed in µg of protein that bound to 1 
mg of SHAS (n=3, mean ± SEM). E) SDS-PAGE before and after binding to SHAS. Line 1, OVA; line 2, 
PBS-Tween20 released OVA; line 3, PBS released OVA.  
 
Fig. 2 OVA488-loaded SHAS is taken up by human and murine DCs without toxic and apoptotic side 
effects 
A) Human mdDCs after 1 h of incubation with SHAS-OVA488 (green: OVA488; white: plasma membrane 
staining (Cellmask Orange); blue: DAPI); two representative pictures taken by confocal microscopy.  
B) Percent of necrotic and apoptotic human mdDCs after 24 h contact with different concentrations 
of OVA488, SHAS or SHAS-OVA488 as determined by 7AAD and anti-annexin staining by flow cytometry 
(representative plots, n=3). 
C) Flow cytometry analysis of the uptake of OVA488 by migratory DCs migrated to the draining 
inguinal lymph node of B6-WT mice 1 day after injection of either PBS, soluble OVA488 or SHAS-
OVA488 into the lumbar area of the mice (representative plots, n=2-3).  
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D) Percentage of CD11b+ migratory DCs in the draining inguinal lymph node of B6-WT mice which 
have taken up OVA488 (DyLight488
+), 1, 4 or 7 days after injection of soluble OVA488 or SHAS-OVA488 
into the lumbar area of the mice (representative plots, n=2-3).  
 
Fig. 3 SHAS-OVA induces a stronger OVA-specific CD8+ (OT-I) and CD4+ (OT-II) T- cell proliferation 
compared to OVA. 
CellTraceViolet (CTV)- labeled OVA-specific CD8+ (OT-I) and CD4+ (OT-II) T cells were adoptively 
transferred in WT C57/BL6 mice 3, 6 or 8 days after the s.c. injection of OVA488 or SHAS-OVA488. The 
proliferation was assessed in the spleen 3 days later by flow cytometry. After gating on CD45.1+ CD3+ 
TCRVα2+ CD8+ or CD4+ cells, proliferation was assessed by the dilution of CTV. For experimental 
protocol see Fig. 6A.  Percentage of proliferating OT-I (A) and OT-II T cells (B) is depicted.  Significant 
differences among the groups are marked (*, p < 0.05; ***, p < 0.001; Two-tailed Mann-Whitney 
test). Each group consisted of 4 animals. 
 
Fig. 4 OVA-specific IgE and IgG responses to SHAS-bound OVA are comparable to those obtained 
with soluble OVA. 
BALB/c mice were sensitized s.c. with PBS, OVA, SHAS-OVA or SHAS, or i.p with Alum-OVA. The 
appearance of immunoglobulins in serum was monitored, as well as the number of eosinophils in 
BAL after OVA challenge as an indicator of inflammation. For experimental protocol see Fig. S1B. A-C 
Immunoglobulin levels 26 days after the first injection. D) Percentage of eosinophils in BAL fluid after 
OVA challenge. Different capital letters indicate significant differences among the groups (p < 0.05, 
Two-tailed Mann-Whitney test). OVA and SHAS-OVA treated groups consisted of 5 animals, except 
for the SHAS-OVA group in panel D which consisted of 4 animals; PBS, SHAS and Alum-OVA treated 
groups consisted of 4 animals. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Fig. 5 SHAS immunotherapy has reduced side effects.  
After sensitization with Alum adsorbed OVA, mice were treated with two s.c. injections of OVA, SHAS 
or SHAS-OVA (0.2 mg OVA) on days 21 and 28. As a control, higher amounts were injected three 
times every second day (OVA-Ctrl). Serum samples were collected throughout the experiment as 
well as the BAL fluid after sacrifice. For experimental protocol see Fig. S1C. A) Symptoms score 45 
min after the first immunotherapeutic injection (day 21). B) Symptoms score 45 min after the last 
immunotherapeutic injection (day 23 for the OVA-Ctrl group, day 28 for the other groups). C) 
Absolute number of eosinophils in BAL fluid after OVA sensitization, immunotherapy and aerosol 
challenge (day 40). D) Serum concentration of IgG1 before the challenge, i.e. at the end of 
immunotherapy phase (day 35). Significant differences among the groups are marked (*, p < 0.05; 
**, p < 0.01; Two-tailed Mann-Whitney test). Each group consisted of 6 animals, except for the SHAS 
control group, which consisted of 4 animals. 
 
Fig. S1 Immunisation protocols for the data shown in Fig. 3 (A), Fig. 4 (B) and Fig. 5 (C).  
A) T cell immune response in vivo: C57BL/6 mice were injected s.c. in the lumbar area with 200 
l of a solution containing 20 g OVA, bound or not bound to SHAS. After 3, 6 or 8 days, 106 
of both CTV labeled OT-I and OT-II cells were injected i.v. Three days later, splenocytes were 
isolated and analyzed by flow cytometry.  
 
B) Humoral immune response in vivo: To characterize the immune responses to antigens delivered 
through SHAS, wild-type BALB/c mice were sensitized using an adjuvant-free protocol as described 
(12), with 3 s.c. injections of 10 g OVA in solution or bound to SHAS on days 0, 7 and 14. Negative 
control mice were injected with the corresponding amounts of SHAS or PBS and a positive control 
group of mice was injected i.p. with 10 g OVA absorbed to 500 g Alum (Imject Alum, Thermo 
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Scientific). Mice were challenged on days 26, 27, 28 with 1% OVA aerosols for 20 min and sacrificed 
on day 30. Blood samples were taken with the tail cut method (21) on days 0, 14, 26 and 30 and the 
concentration of OVA-specific IgE, IgG1 and IgG2a was determined by ELISA. Mice were sacrificed on 
day 30 and BAL was obtained. 
C) Immunotherapy model: The possibility of using SHAS for immunotherapeutic purposes was 
investigated using a previously described allergy model (14). Wild-type BALB/c mice were sensitized 
with two i.p. injections of 10 g OVA precipitated together with 2.25 mg Alum on days 0 and 7. Mice 
were then treated with two s.c. injections of 0.2 mg OVA, SHAS-OVA or protein-free SHAS on day 21 
and 28. On days 21 and 28 (or day 23 for the OVA-Ctrl group), a symptom score was determined. The 
control immunotherapy group (OVA-ctrl) was treated with three s.c. injections of 1 mg OVA on days 
21, 23, 25 (14). On days 35, 37 and 39 mice were challenged with 1% OVA aerosols for 20 min and 
sacrificed on day 40 and BAL was obtained. 
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